Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Cobra Biomanufacturing" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Cobra Biomanufacturing for you to read. Along with our medical data and news we also list Cobra Biomanufacturing Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cobra Biomanufacturing Companies for you to search.
The company expects to invest up to $200m in the approximately 120,000ft² biomanufacturing plant at its West Greenwich campus in Rhode Island. Amgen will use its next-generation biomanufacturing The post Amgen breaks ground on $200m biomanufacturing facility in US appeared first on Pharma Business review.
The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products. KEELE, England–(BUSINESS WIRE)–Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”), today announced that it … Continue reading → Cet article Cobra Biolog...
NewsAmgen announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States, will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets.
California-based biotech firm Amgen is planning to build a $160 million biomanufacturing plant in Rhode Island. -More-
Amgen has broken ground on the construction of its West Greenwich, Rhode Island-based 120,000-square-foot biomanufacturing facility.
Amgen has announced it is building a ‘next-generation’ biomanufacturing plant at its West Greenwich campus in Rhode Island. The first...Read More... The post Amgen to build new biomanufacturing plant in Rhode Island, US appeared first on Pharmaceutical Technology.
Rhode Island will be the home of Amgenâs first US next-generation biomanufacturing plant, based on the firmâs modular, single-use site in Singapore.
The Plant Will be First-of-its-Kind in the U.S. THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to ma...
Celebrating the crème-de-la-crème of life sciences talent in the North of England and sponsored by Manchester Science Partnerships, the awards ceremony recognised the biomedical industry’s highest achievers. Around 400 people attended the gala dinner at The Mere Golf Resort and Spa, Cheshire, hosted by comedian and broadcaster Paul Sinha, one of the stars of the ITV quiz The Chase. The team at...
NewsWuXi will invest $392M to build the facility, which will deploy multiple single-use bioreactors for commercial biomanufacturing and is also designed to be able to run continuous bioprocessing.
Tech company, Univercells, and Global Health Investment Fund (GHIF) have announced the closing of a €16 million Series B equity financing round, which will support the continued development of Univercell’s biomanufacturing technology.
China-based WuXi Biologics is set to construct a biologics drug substance manufacturing facility worth about €325m in Dundalk, Ireland. The...Read More... The post WuXi Biologics to build €325m biomanufacturing facility in Ireland appeared first on Pharmaceutical Technology.
Keele and Manchester, UK, 24 September 2015: Cobra Biologics, international CDMO of biologics and pharmaceuticals, and Alan Dickson, Professor of Biotechnology at The University of Manchester (UoM) today announced a two year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported via the F...
WuXi Biologics is to invest $392 million to build a new biologics drug substance manufacturing facility in Ireland. The new facility will use single-use bioreactors for commercial biomanufacturing. This is also WuXi Biologics’ first manufacturing site outside of China. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed. This facility will create approxi...
The CMO Leadership Awards are organised by Life Science Leader magazine and recipients determined through customer feedback collected by Industry Standard Research (ISR). For the 2018 awards, which will be presented at a reception dinner at The W Hotel in New York City on March 21, more than 110 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufactu...
The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products. 21 April 2018, Keele, UK: Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”), today announced that it has been awarded the Queen’s Award 2018 f...
Cobra Biologics and Tecrea, a cell delivery biotechnology company, have been awarded a 15 month collaborative grant of £112,291 ($166,000 USD) by the UK’s innovation agency, Innovate UK for the development of a scalable Adeno Associated Virus (AAV) production bioprocess.The grant is awarded under Innovate UK’s ‘Technology Inspired Innovation’ competition, which aims t...
New $160-million biomanufacturing plant in RI to create 150 additional highly-skilled jobs
Cobra Biologics Ltd (Cobra), international CDMO of biologics and pharmaceuticals, and the Centre for Process Innovation (CPI), a UK-based technology innovation centre, are collaborating on a project which will focus on the development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine. The £1.8M project, which...
US drugmaker Amgen has opted to go stateside with the location of a facility that it calls a ‘next-generation…
Cobra’s objective in the UK is to become a centre of excellence for the manufacturing of AMTs from pre-clinical to commercial supply. They already have a global reputation GMP manufacturing in this area and are looking forward to further expansion to commercial supply in this exciting and innovative sector.As you may be aware, Cobra Biologics has been intrinsically linked to Cell and Gene Th...
Partnership empowers Alegeus clients to deliver market-leading COBRA capabilities under their brand Alegeus, the market leader in consumer directed healthcare (CDH) solutions, and
Coming to Rhode Island, the facility is first of its kind in the U.S., according to Amgen, and will feature primarily single-use systems and a modular design.
Samsung plans to invest KRW 180 trillion into its various businesses over the next three years, including in biomanufacturing-focused Samsung BioLogics.